| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 616.29M | $ 329.00M | $ 233.66M | $ 2.79M | $ 6.69M |
| Gross Profit | $ 515.57M | $ 290.52M | $ 219.53M | $ 2.52M | $ 5.90M |
| Operating Income | $ 123.32M | $ 41.93M | $ 20.63M | $ -218.32M | $ -344.77M |
| EBITDA | $ 134.36M | $ 49.90M | $ 26.10M | $ -213.11M | $ -341.97M |
| Net Income | $ 447.18M | $ 23.38M | $ 12.67M | $ -223.81M | $ -348.10M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 141.97M | $ 311.00M | $ 217.51M | $ 161.68M | $ 314.76M |
| Total Assets | $ 1.06B | $ 577.69M | $ 329.59M | $ 193.57M | $ 379.63M |
| Total Debt | $ 260.73M | $ 253.72M | $ 110.80M | $ 83.06M | $ 79.05M |
| Net Debt | $ 181.58M | $ 73.83M | $ 17.86M | $ -19.24M | $ -219.84M |
| Total Liabilities | $ 415.23M | $ 355.33M | $ 169.09M | $ 134.99M | $ 142.48M |
| Stockholders' Equity | $ 648.02M | $ 222.36M | $ 160.50M | $ 58.59M | $ 237.15M |
| Cash Flow | |||||
| Free Cash Flow | $ -24.99M | $ -40.56M | $ -31.41M | $ -176.18M | $ -296.04M |
| Operating Cash Flow | $ -24.77M | $ -40.52M | $ -31.41M | $ -176.17M | $ -295.63M |
| Investing Cash Flow | $ 13.80M | $ -1.04M | $ -50.65M | $ -20.01M | $ -332.00K |
| Financing Cash Flow | $ -89.73M | $ 128.53M | $ 72.70M | $ -391.00K | $ 41.42M |
TG Therapeutics (CH:NKB2)
:NKB2
